Could a Vaccine-Like shot slow Alzheimer's? new trial launches

NCT ID NCT05606341

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a drug called CpG1018, which aims to stimulate the immune system to fight Alzheimer's disease. It involves 18 people with mild cognitive impairment or mild Alzheimer's. The main goal is to check safety, not yet to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CpG1018 (a drug that stimulates the immune system)
What this could lead to: If safe, this could point toward a new way to slow early Alzheimer's by boosting the body's natural immune response.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. It may not show any benefit, and there are risks like autoimmune reactions or brain swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DEMENTIA MILD COGNITIVE IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.